Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status

Days after scoring expanded approval for its potential blockbuster anemia therapy, Acceleron has the FDA fawning over its experimental drug sotatercept — with the US regulator granting the potential pulmonary arterial hypertension drug breakthrough status.